For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Making sure that scientists have the best possible reagents for their research has been one of our core values since Abcam's earliest beginnings. By providing researchers with reagents that work first time, we are helping to speed up the progress of scientific discovery. That's why we're very happy to announce our recent awards from the 2017 CiteAb Antibody Awards:
Dr Chalmers said: “This award is made on CiteAb data or the highest total number of citations per antibody (primary and secondary) for the period between January 2016 and December 2016.
“To step up and claim the number one position here demonstrates that some really hard work done by the Abcam team over recent years is now paying dividends. We congratulate Abcam on their excellent win!”
We started our knockout (KO) validation initiative in 2015 and we've now validated the specificity of several hundred antibodies using CRISPR-Cas9 technology. This ongoing program is being conducted at an unprecedented scale and is central to our commitment to improving the standards of antibody validation.
Dr Andrew Chalmers said: “We’ve been very involved in the antibody validation movement over the past two years, and saw a number of excellent initiatives discussed at the 2nd International Antibody Validation event we co-hosted in September. We were thrilled to see an excellent standard of entry in this extremely important category, and congratulate Abcam on their deserved win.”